A new study into the online conversations of healthcare professionals discussing prostate cancer has revealed a strong focus on emerging therapies, the latest clinical trials, AI-driven diagnostics ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...
Sinar Daily on MSN2d
Seven-year trial shows 48 per cent survival with dual immunotherapyPatients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback